Literature DB >> 7066166

Spironolactone dose-response relationships in healthy subjects.

G T McInnes, R M Perkins, J R Shelton, I R Harrison.   

Abstract

1 The effect of single oral doses of spironolactone 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and placebo in reversing the urinary electrolyte changes induced by fludrocortisone between 2-10 h and 12-16 h after treatment was examined in healthy subjects. 2 In the two collection periods, there were statistically significant log linear dose-response relationships for sodium excretion (P less than 0.001), potassium excretion (P less than 0.001 and P less than 0.025 respectively) and log10 10 Na/K (P less than 0.001). 3 However, there was evidence that the log spironolactone dose-urinary sodium responses did not increase monotonically, while the relationship for urinary potassium appeared to enter the lower 'plateau' at doses between 100 mg and 200 mg, and when compared to placebo values, potassium excretion was not significantly depressed 12-16 h after treatment (P greater than 0.1). Thus, sodium and potassium responses were dissociated in dose producing maximal effect and in duration of activity, reinforcing the view that functions or the urinary sodium/potassium ratio alone cannot be considered an adequate description of renal antimineralocorticoid activity. 4 Dose-response relationships for all urinary electrolyte variables seem consistently steep and linear between 25 mg and 100 mg of spironolactone, suggesting that, in studies employing this model, the doses of spironolactone should be restricted to this range.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066166      PMCID: PMC1402049          DOI: 10.1111/j.1365-2125.1982.tb01413.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  Spironolactone.

Authors:  H R Ochs; D J Greenblatt; G Bodem; T W Smith
Journal:  Am Heart J       Date:  1978-09       Impact factor: 4.749

2.  Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.

Authors:  W Sadée; R Schröder; E von Leitner; M Dagcioglu
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

3.  High doses of spironolactone in the treatment of liver cirrhosis with ascites.

Authors:  N Papadoyanakis; J Darsinos; K Alexandrou; J Karli
Journal:  Br J Clin Pract       Date:  1972-01

4.  Relative potency of prorenoate and spironolactone in normal man.

Authors:  L Ramsay; I Harrison; J Shelton; M Tidd
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

5.  Spironolactone. I. Disposition and metabolism.

Authors:  A Karim; J Zagarella; J Hribar; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

6.  Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.

Authors:  A Karim; J Zagarella; T C Hutsell; M Dooley
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

7.  Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension.

Authors:  R K Ferguson; D M Turek; D R Rovner
Journal:  Clin Pharmacol Ther       Date:  1977-01       Impact factor: 6.875

8.  Spironolactone and potassium canrenoate in normal man.

Authors:  L Ramsay; J Shelton; I Harrison; M Tidd; M Asbury
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

9.  Agonist and antimineralocorticoid activities of spirolactones.

Authors:  C Sakauye; D Feldman
Journal:  Am J Physiol       Date:  1976-07

10.  Spironolactone and canrenoate-K: relative potency at steady state.

Authors:  L Ramsay; M Asbury; J Shelton; I Harrison
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

View more
  7 in total

Review 1.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

2.  A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone.

Authors:  Erfan Maddah; K Melissa Hallow
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-07-01       Impact factor: 2.410

3.  Metabolic effects of high dose amiloride and spironolactone: a comparative study in normal subjects.

Authors:  J A Millar; R Fraser; P Mason; B Leckie; A M Cumming; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

Review 4.  Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.

Authors:  Sara S Roscioni; Dick de Zeeuw; Stephan J L Bakker; Hiddo J Lambers Heerspink
Journal:  Nat Rev Nephrol       Date:  2012-10-16       Impact factor: 28.314

5.  First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis.

Authors:  Robert W Hunter; Rebecca Moorhouse; Tariq E Farrah; Iain M MacIntyre; Takae Asai; Peter J Gallacher; Debbie Kerr; Vanessa Melville; Alicja Czopek; Emma E Morrison; Jess R Ivy; James W Dear; Matthew A Bailey; Jane Goddard; David J Webb; Neeraj Dhaun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

6.  The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale.

Authors:  Alhasan Mujtaba; Mohammed A Taher; Mazin A Hazza; Hassan M Al-Rubaye; Asaad H Kata; Hamid AbdulWahab; AbdulAmeer AbdulBari; Hayder K AlRubay
Journal:  Cardiol Ther       Date:  2018-05-21

7.  PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.

Authors:  Stephen Orena; Tristan S Maurer; Li She; Rena Eudy; Vincent Bernardo; Darla Dash; Paula Loria; Mary E Banker; Meera Tugnait; Carlin V Okerberg; Jessie Qian; Carine M Boustany-Kari
Journal:  Front Pharmacol       Date:  2013-10-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.